



Transpek Industry Limited

Reg. Office:

4th Floor, Lilleria 1038

Gotri - Sevasi Road

Vadodara - 390021, Gujarat, (India)

Sec/Unaudited Fin Results/2025/

Date: 5th August, 2025

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400 001

Ref: Scrip Code: 506687

Sub: Unaudited Financial Results of the Company for the quarter ended 30th June, 2025

Dear Sir/Madam,

The Board of Directors of the Company at its meeting held today approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th June, 2025 which were earlier reviewed by the Audit Committee of the Company at its meeting held on 05/08/2025.

The Meeting started at 2.00 p.m. and concluded 05.30 p.m.


The trading Window which was closed from 1st July, 2025 shall re-open from 8th August, 2025.

You are requested to take the above information on record.

Thanking you,

Yours faithfully,

For Transpek Industry Limited


Alak D. Vyas

Company Secretary &

Compliance Officer

ACS: 31731

Alak/Richa



Works:
At & Post: Ekalbura
Taluka Padra
Dist.: Vadodara - 391 440
Gujarat (India)
Ph.: +91-2662-244444, 244318, 244309
Fax: +91-2662-244439, 244207



Company Identification No.: L23205GJ1965PLC001343

www.transpek.com
WEBSITE
inquiry@transpek.com
EMAIL

Independent Auditor's Review Report on Unaudited Quarterly Standalone Financial Results of Transpek Industry Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To the Board of Directors,
Transpek Industry Limited**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Transpek Industry Limited** ("the Company") for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) 34, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Mumbai | Delhi | Surat | Chennai | Hyderabad

11/13, Botawala Building, 2nd Floor, Horniman Circle, Fort, Mumbai 400 001, India

+91 22 2266 1255/ 0275/ 0821/ 1557 | Fax: +91 022 2266 5666 | bsmco.bbo@bansimehta.com | www.bansimehta.com

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, as amended from time to time, including the manner in which it is to be disclosed, or that it contains any material misstatement.

PLACE : Mumbai
DATED : August 5, 2025



For **BANSI S. MEHTA & CO.**
Chartered Accountants
Firm Registration No. 100991W

PARESH H. CLERK
Partner
Membership No. 036148
UDIN : 25036148BMKSYY4656

Independent Auditor's Review Report on Unaudited Quarterly Consolidated Financial Results of Transpek Industry Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To the Board of Directors,
Transpek Industry Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Transpek Industry Limited** ("the Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the management of the Holding Company and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) 34, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Mumbai | Delhi | Surat | Chennai | Hyderabad

11/13, Botawala Building, 2nd Floor, Horniman Circle, Fort, Mumbai 400 001, India

+91 22 2266 1255/ 0275/ 0821/ 1557 | Fax: +91 022 2266 5666 | bsmco.bbo@bansimehta.com | www.bansimehta.com

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entity:

Name of the Entity	Relationship
Transpek Creative Chemistry Private Limited	Wholly owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, as amended from time to time, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **BANSI S. MEHTA & CO.**
Chartered Accountants
Firm Registration No. 100991W



PARESH H. CLERK
Partner

Membership No. 036148
UDIN : 25036148BMKSYZ9605

PLACE : Mumbai
DATED : August 5, 2025

STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		June 30, 2025 (Unaudited)	March 31, 2025 (Audited)	June 30, 2024 (Unaudited)	March 31, 2025 (Audited)	June 30, 2025 (Unaudited)	March 31, 2025 (Audited)	June 30, 2024 (Unaudited)	March 31, 2025 (Audited)
I	Revenue from Operations	15,423.32	16,525.65	15,186.07	64,985.31	15,423.32	16,525.65	15,186.07	64,985.31
II	Other Income	1,166.13	774.31	1,097.95	2,870.78	1,166.13	774.31	1,097.95	2,870.78
III	Total Income (I+II)	16,589.45	17,299.96	16,284.02	67,856.09	16,589.45	17,299.96	16,284.02	67,856.09
IV	Expenses								
	a. Cost of Materials Consumed	7,689.84	8,357.39	6,818.92	33,032.69	7,689.84	8,357.39	6,818.92	33,032.69
	b. Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-progress	(21.95)	166.35	1,054.08	213.73	(21.95)	166.35	1,054.08	213.73
	c. Employee Benefits Expense	1,831.57	1,586.07	1,675.79	6,662.82	1,831.57	1,586.07	1,675.79	6,662.82
	d. Finance Costs	245.75	279.18	300.65	1,174.31	245.75	279.18	300.65	1,174.31
	e. Depreciation and Amortisation Expense	1,232.17	1,263.96	1,232.36	4,998.93	1,232.17	1,263.96	1,232.36	4,998.93
	f. Other Expenses	3,518.96	3,194.53	4,035.84	15,607.68	3,519.00	3,194.57	4,035.97	15,608.06
	Total Expenses (IV)	14,496.34	14,847.48	15,117.64	61,690.16	14,496.38	14,847.52	15,117.77	61,690.54
V	Profit / (Loss) before Exceptional Items and Tax (III-IV)	2,093.11	2,452.48	1,166.38	6,165.93	2,093.07	2,452.44	1,166.25	6,165.56
VI	Exceptional Items	-	-	-	-	-	-	-	-
VII	Profit / (Loss) before Tax (V+VI)	2,093.11	2,452.48	1,166.38	6,165.93	2,093.07	2,452.44	1,166.25	6,165.56
VIII	Tax Expense								
	a. Current Tax	517.00	640.00	303.00	1,670.00	517.00	640.00	303.00	1,670.00
	b. Deferred Tax	18.00	(112.72)	(65.65)	(353.16)	18.00	(112.72)	(65.65)	(353.16)
	c. Excess / (Short) Provision for tax of earlier years	-	0.03	-	(24.98)	-	0.03	-	(24.98)
	Total Tax Expense (VIII)	535.00	527.31	237.35	1,291.86	535.00	527.31	237.35	1,291.86
IX	Profit / (Loss) for the period (VII-VIII)	1,558.11	1,925.17	929.03	4,874.07	1,558.07	1,925.13	928.90	4,873.70

₹ in Lakhs



STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

	Particulars	Standalone			Consolidated		
		Quarter Ended		Year Ended	Quarter Ended		Year Ended
		June 30, 2025 (Unaudited)	March 31, 2025 (Audited)	June 30, 2024 (Unaudited)	June 30, 2025 (Unaudited)	March 31, 2025 (Audited)	June 30, 2024 (Unaudited)
X	Other Comprehensive Income :						
	Items that will not be reclassified to profit or loss						
	a. Remeasurement gain / (loss) on Defined Benefit Plans	(5.53)	131.52	(11.56)	(5.53)	131.52	(11.56)
	b. Effect of measuring Equity Instruments at Fair Value	445.43	(4,443.17)	728.81	445.43	(4,443.17)	728.81
	c. Income Tax on above	(62.31)	727.79	(80.47)	(62.31)	727.79	(80.47)
	Total Other Comprehensive Income (X)	377.59	(3,583.85)	636.78	377.59	(3,583.85)	636.78
XI	Total Comprehensive Income for the period (IX+X)	1,935.70	(1,658.69)	1,565.81	1,935.66	(1,658.73)	1,565.68
XII	Paid up Equity Share Capital (Face Value ₹ 10 each)	558.56	558.56	558.56	558.56	558.56	558.56
XIII	Other Equity						
XIV	Earnings per share of ₹ 10 each (not annualised):						
	Basic (₹)	27.90	34.47	16.63	27.90	34.47	16.63
	Diluted (₹)	27.90	34.47	16.63	27.90	34.47	16.63
	See accompanying notes to the Financial Results						

Notes :

- The above results which are published have been reviewed and recommended by the Audit Committee at its meeting held on August 5, 2025 and approved by the Board of Directors of the Company at its meeting held on August 5, 2025. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results. The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and the other accounting principles generally accepted in India. The figures for the quarter ended March 31, 2025 as reported in these financial results are balancing figures between the audited figures for the full financial year ended March 31, 2025 and published year to date figures upto the end of the third quarter of the financial year ended March 31, 2025, which were subjected to limited review.
- The Company is engaged in the business of manufacturing of "Chemicals", which is the only Operating Segment as per Ind AS 108.
- Consolidated Financial Results include result of a Wholly Owned Subsidiary, viz., Transpek Creative Chemistry Private Limited.

For TRANSPK INDUSTRY LIMITED

Bimal V. Mehta
BIMAL V. MEHTA
 MANAGING DIRECTOR
 DIN: 00081171



DATE: August 5, 2025
 PLACE: Vadodara